Hematology News

World Thrombosis Day is observed today to increase global awareness about the condition, including its causes, risk factors, symptoms, and prevention and treatment strategies.

Humans are born with a risk for developing, at some point in their life, one of more than 40 disorders that clinicians have identified to have some connection with genetics, according to the National Human Genome Research Institute.

ASH has initiated an effort to develop clinical practice guidelines for the management of sickle cell disease.

ASH presented $150,000 to five investigators through the society’s bridge grant program, designed to sustain promising hematologic research proposals that are not funded through NIH.

Critically ill adults who received allogeneic red cells stored for a longer duration had comparable 90-day mortality rates as adults who received the freshest cells, according to results of an international, multicenter, randomized double-blind trial published in The New England Journal of Medicine.

National Sickle Cell Awareness Month — observed in September — draws attention to the collection of inherited blood disorders that affect up to 100,000 Americans.

Patients treated with dabigatran for nonvalvular atrial fibrillation appeared to be at higher risk for 30-day hospital readmission due to bleeding, according to a population-based, retrospective cohort study.

Individuals with sickle cell disease demonstrated more than double the risk for leukemia compared with the general population, according to an analysis of population-based data from California.

An investigational, engineered therapy that mimics clotting enzyme ADAMTS-13 demonstrated safety and efficacy in patients with hereditary thrombotic thrombocytopenic purpura, according to multicenter study results published in Blood.

ASH selected 20 hematology trainees and early career faculty members to participate in the ASH Clinical Research Training Institute.